Logo
x

Search category

Subscribe Now

Daiichi Sankyo

Daiichi Sankyo and AstraZeneca Report P-III Trial (TROPION-Breast01) Results of Datopotamab Deruxtecan for Breast Cancer

Daiichi Sankyo and AstraZeneca Report P-III Trial (TROPION-Breast01) Results of Datopotamab Deruxtecan for Breast Cancer

  • September 22, 2023
Daiichi Sankyo Presents P-II Trial (HERTHENA-Lung01) Results of Patritumab Deruxtecan for EGFR-Mutated Metastatic NSCLC at WCLC 2023

Daiichi Sankyo Presents P-II Trial (HERTHENA-Lung01) Results of Patritumab Deruxtecan for EGFR-Mutated Metastatic NSCLC at WCLC 20...

  • September 11, 2023
Daiichi Sankyo Receives Two Breakthrough Therapy Designations from the US FDA for Enhertu to Treat Multiple HER2 Expressing Cancers

Daiichi Sankyo Receives Two Breakthrough Therapy Designations from the US FDA for Enhertu to Treat Multiple HER2 Expressing Cancer...

  • September 1, 2023
Daiichi Sankyo’s Enhertu Receives the MHLW’s Approval as First HER2 Directed Therapy for HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo’s Enhertu Receives the MHLW’s Approval as First HER2 Directed Therapy for HER2 Mutant Metastatic Non-Small Cell Lun...

  • August 23, 2023
Daiichi Sankyo Reports the Commercial Availability of Vanflyta (quizartinib) in the US for Newly Diagnosed FLT3-ITD Positive AML

Daiichi Sankyo Reports the Commercial Availability of Vanflyta (quizartinib) in the US for Newly Diagnosed FLT3-ITD Positive AML

  • August 10, 2023
Daiichi Sankyo and AstraZeneca Report P-II trial (DESTINY-PanTumor02) Results of Enhertu (trastuzumab deruxtecan) for HER2 Expressing Advanced Solid Tumors

Daiichi Sankyo and AstraZeneca Report P-II trial (DESTINY-PanTumor02) Results of Enhertu (trastuzumab deruxtecan) for HER2 Express...

  • July 27, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.